Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer

Inclusion Criteria:

* History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease.

Confirmation of diagnosis must be performed at MSKCC.

* Patient's liver metastases must be deemed unresectable and comprise \<70% of the liver parenchyma.
* A patient may have had prior chemotherapy or be previously untreated.
* Patient may not have received prior treatment with FUDR or \>2 doses of Oxaliplatin.
* KPS \> or = to 60%.
* WBC \> or = to 3,000 cells/mm3 and platelet count \> or = to 100,000 cells/mm3 within 14 days of registration.
* Creatinine \< or = to 1.5 mg/dl within 14 days of registration.
* Total serum bilirubin \< or = 2.0 mg/dl within 14 days of registration.

Exclusion Criteria:

* No active concurrent malignancies: except a patient's potentially resectable colorectal primary.
* Patient must not have obstruction of GI or GU tract.
* Patient must not have current, symptomatic peripheral sensory neuropathy.
* No prior radiation to liver.
* No active infection, ascites, or hepatic encephalopathy.
* Age ≥ 18 years.
* Female patients cannot be pregnant or lactating.
* Signed informed consent.